Product Code: BIO232A
Highlights:
The global human recombinant DNA market should reach $348.7 billion by 2022 and more than $496.9 billion by 2027, with a compound annual growth rate (CAGR) of 7.3% during the forecast period of 2022-2027.
North American human recombinant DNA market should reach $150.8 billion by 2022 and more than $191.7 billion by 2027, with a CAGR of 4.9% during the forecast period of 2022-2027.
Asia-Pacific human recombinant DNA market should reach $86 billion by 2022 and more than $136.2 billion by 2027, with a CAGR of 9.6% during the forecast period of 2022-2027.
Report Scope:
This report highlights the current and future market potential for human recombinant DNA and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities, trends and key players in the market. The report also provides market projections from 2022 through 2027. An in-depth discussion of strategic alliances, industry structures, competitive dynamics, and market forces are also provided.
Report Includes:
- 24 data tables and 8 additional tables
- An overview of the global market for human recombinant DNA
- Estimation of the market size and analyses of global market trends, with data from 2020, 2021 with projections of compound annual growth rates (CAGRs) through 2026
- Highlights of the market potential for human recombinant DNA, based on product, application, and region
- Coverage of history and future of human recombinant DNA, and latest technological advancements of the industry
- Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast
- Coverage of regulatory landscape, product recalls, pipeline products, and discussion on future perspective, strategies, and developments of the industry
- Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies and a relevant patent analysis
- Company profiles of major players within the industry AbbVie Inc., Amgen Inc., Eli Lilly, Sanofi
Table of Contents
Chapter 1 Introduction
- Introduction
- Study Goals and Objectives
- Reasons for Doing the Study
- Intended Audience
- Scope and Format
- Methodology
- Market Estimates
- Information Sources
- Geographical Breakdown
- Analyst's Credentials
- BCC Custom Research
- Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
- Homologous Recombination (HR)
- Targets for Cancer Therapy
Chapter 4 Impact of COVID-19 Pandemic
Chapter 5 Market Dynamics
- Market Drivers
- Increasing Incidences of Chronic Diseases
- Growing Aging Population
- Advancements in Manufacturing Technologies
- Market Restraints
- Price Controls
- Entry of Biosimilars
- Opportunities
- Untapped Potential in Emerging Markets
Chapter 6 Market Breakdown by Product Type
- Human Protein Replacements
- Market Size and Forecast
- Therapeutic Agents for Human Diseases
- Market Size and Forecast
- Vaccines
- Types of Vaccines
- Market Size and Forecast
Chapter 7 Market Breakdown by End User
- Biotechnology and Pharmaceutical Industry
- Market Size and Forecast
- Research Laboratories and Academic Institutes
- Market Size and Forecast
Chapter 8 Market Breakdown by Region
- Global Market by Region
- North America
- Europe
- Asia-Pacific
- Rest of the World
Chapter 9 Competitive Landscape
Chapter 10 Company Profiles
- ABBVIE INC.
- ALEXION PHARMACEUTICALS
- AMGEN INC.
- ELI LILLY
- MERCK & CO. INC.
- SANOFI S.A.
- TAKEDA PHARMACEUTICAL CO LTD.